- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03958032
Effects of Sarcopenia on Early Postoperative Outcomes in Patients Undergoing Surgical Treatment for Gastric Cancer
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Among gastrointestinal disease, gastric cancer is a malignancy which is diagnosed predominantly in advanced stages, mostly accompanied with malnutrition when diagnosed, has aggressive behavior with poor oncological outcomes. The only option for curative treatment is surgical resection in this malignancy; however, the surgical procedure itself causes high morbidity and mortality rates. Therefore, physicians combine various treatment modalities and risk assessment to decrease complication and mortality rates.
Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life, and death. For the diagnosis of sarcopenia, using the presence of both low muscle mass and decreased muscle function (strength or performance) is recommended. Previous studies showed that colorectal or pancreatic cancer accompanied with sarcopenia has adverse effects on not only for short term and also for long term outcomes. The majority of studies regarding gastric cancer was published from Eastern countries owing to their high incidence. There are few studies from western countries which are mostly retrospective and does not meet the diagnostic criteria of sarcopenia. In the western population, there is no high-quality evidence so far regarding the impact of sarcopenia on early outcomes of gastric cancer surgical treatment.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Trabzon, Tacchino, 61080
- Karadeniz Technical University, Faculty of Medicine
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Patients undergoing gastric surgery for gastric cancer
- Histologically proven gastric adenocarcinoma
- Patients over 18 years
- Patients who agreed to participate in the study
Exclusion Criteria:
- patients treated by non-surgical treatment such as endoscopic treatment, palliative chemotherapy)
- patients received palliative surgery without gastric resection (bypass procedures)
- patients required thoracotomy/thoracoscopy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Participants with gastric cancer
All consecutive patients undergoing surgery due to gastric cancer will be included in this study.
|
No intervention is planned for the participants for the treatment of gastric cancer.
Treatment decision will be in line with clinical practice guidelines.
Surgical team will be blind to the participant's sarcopenia status.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Postoperative complications
Lasso di tempo: within 30 days after surgery
|
complications graded by Clavien-Dindo Complication Classification System
|
within 30 days after surgery
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Length of hospital stay
Lasso di tempo: up to 90 days
|
time interval from the date of operation to the date of discharge
|
up to 90 days
|
|
Mortality
Lasso di tempo: within 30 days after surgery
|
Dying after surgery
|
within 30 days after surgery
|
|
Readmission rate
Lasso di tempo: within 30 days after surgery
|
readmission to the hospital because of the adverse events after discharge
|
within 30 days after surgery
|
|
Incidence of sarcopenia
Lasso di tempo: one day before surgery
|
Sarcopenia consensus defined by The European Working Group on Sarcopenia in Older People
|
one day before surgery
|
|
Muscle mass volume
Lasso di tempo: one day before surgery
|
muscle mass volume of a cross-sectional computerized- tomography image of the L3, corrected for patient height resulting in L3 muscle index.
|
one day before surgery
|
|
Psoas muscle mass volume
Lasso di tempo: one day before surgery
|
muscle mass volume of Psoas muscle with 3D reconstruction
|
one day before surgery
|
|
Muscle strength
Lasso di tempo: one day before surgery
|
evaluated by handgrip strength test (with digital dynamometer)
|
one day before surgery
|
|
Physical performance
Lasso di tempo: one day before surgery
|
evaluated by 4-meter gait speed test
|
one day before surgery
|
|
Major complication
Lasso di tempo: within 30 days after surgery
|
grade 3 or higher complications graded by Clavien-Dindo Complication Classification System
|
within 30 days after surgery
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Ali Guner, MD, Karadeniz Technical University Faculty of Medicine
Pubblicazioni e link utili
Pubblicazioni generali
- Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.
- Fukuda Y, Yamamoto K, Hirao M, Nishikawa K, Nagatsuma Y, Nakayama T, Tanikawa S, Maeda S, Uemura M, Miyake M, Hama N, Miyamoto A, Ikeda M, Nakamori S, Sekimoto M, Fujitani K, Tsujinaka T. Sarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomy. Gastric Cancer. 2016 Jul;19(3):986-93. doi: 10.1007/s10120-015-0546-4. Epub 2015 Sep 25.
- Tegels JJ, van Vugt JL, Reisinger KW, Hulsewe KW, Hoofwijk AG, Derikx JP, Stoot JH. Sarcopenia is highly prevalent in patients undergoing surgery for gastric cancer but not associated with worse outcomes. J Surg Oncol. 2015 Sep;112(4):403-7. doi: 10.1002/jso.24015. Epub 2015 Aug 31.
- Guner A. Recent trends of gastric cancer treatment in Turkey. Transl Gastroenterol Hepatol. 2017 Apr 26;2:31. doi: 10.21037/tgh.2017.04.01. eCollection 2017.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie dell'apparato digerente
- Malattie del sistema nervoso
- Neoplasie
- Neoplasie per sede
- Manifestazioni neurologiche
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie gastrointestinali
- Malattie dello stomaco
- Disturbi della nutrizione
- Peso corporeo
- Manifestazioni neuromuscolari
- Condizioni patologiche, anatomiche
- Cambiamenti di peso corporeo
- Atrofia muscolare
- Atrofia
- Emaciamento
- Perdita di peso
- Neoplasie allo stomaco
- Sarcopenia
- Malnutrizione
- Cachessia
Altri numeri di identificazione dello studio
- sarcopenia01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .